James Scibetta
Director/Board Member at MATINAS BIOPHARMA HOLDINGS, INC.
Net worth: 118 292 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gary Crocker | M | 72 | 20 years | |
| Jerome Jabbour | M | 50 | 11 years | |
| Kristen Williams | F | 50 |
Bioenvision, Inc.
 Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 17 years |
| Herbert Conrad | M | 91 | 11 years | |
| Eric Ende | M | 55 | 7 years | |
| Kathryn Corzo | F | 63 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 4 years |
| Lori Braender | F | 68 | 6 years | |
| Paul Hastings | M | 64 | 13 years | |
| Robert DuBridge | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 8 years |
| Marco Taglietti | M | 64 | 3 years | |
| Mark Froimson | M | 63 | 7 years | |
| Julie Krop | M | 57 | 3 years | |
| Theresa Matkovits | M | 56 | 6 years | |
| Mark Kronenfeld | M | 69 | 11 years | |
| Natasha Giordano | F | 62 | 4 years | |
| Laura Brege | F | 66 | 13 years | |
| Lauren Riker | F | 45 | 12 years | |
| Matthew Wikler | M | 74 | 6 years | |
| Detlev Biniszkiewicz | M | 56 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Hui Liu | M | 56 | 4 years | |
| Susan Mesco | F | - | 9 years | |
| Michael Martin | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Keith Kucinski | M | 55 | 5 years | |
| Ittai Harel | M | 56 |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Jessica Atkinson | F | - |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | 2 years |
| Charles Reinhart | M | 63 | 13 years | |
| Sangeeta Bhatia | M | 55 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| James Ferguson | M | 70 | 5 years | |
| Steven Kafka | M | 54 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Thomas Hoover | M | 55 | 3 years | |
| Christoph Westphal | M | 56 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| William Greene | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 5 years |
| Peter Hutt | M | 89 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| A. Toth | M | 65 | 4 years | |
| Daniel Janney | M | 58 |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | - |
| Dan Hicklin | M | 61 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Pam Stetkiewicz | M | - |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Keith Kendall | M | 66 | 16 years | |
| Mark A. D'Souza | M | - |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| John C. Houghton | M | 60 | 3 years | |
| Gerald J. Kochanski | M | 69 | 5 years | |
| Daron Evans | M | 50 | 7 years | |
| Norman J. Barta | M | 65 | 10 years | |
| Roelof Rongen | M | 59 | 5 years | |
| Gordon J. Fehr | M | 90 |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | 17 years |
| Douglas Bratton | M | 65 | 17 years | |
| Robert J. Mulroy | M | 59 | 17 years | |
| Christopher Barry Wood | M | 78 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 8 years |
| David Luci | M | 57 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 5 years |
| Richard Scranton | M | 57 | 9 years | |
| Stefano Ferrari | M | 55 | 5 years | |
| Luke Evnin | M | 60 | 7 years | |
| Yoshimaru Yamamoto | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | - |
| Yvonne Greenstreet | M | 61 | 9 years | |
| Mark Walters | M | 69 | 5 years | |
| Sylvain Guénette | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Gary Gaglione | M | 72 | 5 years | |
| Dominick DiPaolo | M | 49 | 1 years | |
| Hans-Peter Gerber | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 2 years |
| Roy Winston | M | 63 | - | |
| Gary H. Slatko | M | 67 | - | |
| James van B. Dresser | M | 82 | 15 years | |
| Pat LePore | M | 69 | 3 years | |
| Brian L. Hamilton | M | 76 | 2 years | |
| Dennis L. Winger | M | 77 | 5 years | |
| Me Lisane Dostie | F | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | 8 years |
| Sylvie Bouchard | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Nancy Lurker | F | 66 | 4 years | |
| Carl Gordon | M | 59 | 5 years | |
| Walter M. Lovenberg | M | 89 | 12 years | |
| Sarah Nash | F | 70 | 8 years | |
| Scott Braunstein | M | 60 | 3 years | |
| Fred Middleton | M | 74 | 7 years | |
| Douglas Kling | M | 50 | 2 years | |
| Richard Kahr | M | - | 8 years | |
| Robert J. Weiland | M | 64 | - | |
| Dennis Mcloughlin | M | 58 | - | |
| Peter C. Lewis | M | - | - | |
| Kathleen Gallagher | F | - | 13 years | |
| Vinay Shah | M | 62 | 8 years | |
| Raphael J. Mannino | M | 77 | 7 years | |
| Sergio Alegre | M | - | 4 years | |
| Harry Kovelman | M | 65 | 3 years | |
| Joseph Cooper | M | 66 |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 1 years |
| James B. Jones | M | 59 | - | |
| Paul R. Ellwood | M | - | - | |
| Jacques L. Roy | M | - |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | - |
| Charles Laranjeira | M | 58 | 6 years | |
| Edward J. Stewart | M | 53 | 16 years | |
| William J. Lambert | M | 65 | 4 years | |
| Ernest A. Elgin | M | 58 | 2 years | |
| Vincent Simmon | M | - | - | |
| Thomas Scott Nelson | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | - |
| Taunia S. Markvicka | M | 56 | 8 years | |
| Gary Patou | M | 65 | 6 years | |
| Andrew Saunders | M | - |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | 2 years |
| Lori Kunkel | M | 66 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 6 years |
| Tim M. Ciaccio | M | - | - | |
| Fazal R. Khan | M | 74 | - | |
| Jim Murray | M | - | 14 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 95 | 95.00% |
| Canada | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Scibetta
- Personal Network
